Not yet recruitingInterventionalPhase 1Phase 2Last updated Aug 12, 2026

A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma

A Phase I/II Clinical Trial to Evaluate the Safety, Efficacy, and Cellular Kinetics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma

Overview

ClinicalTrials.gov ID: NCT07760454
Lead Sponsor: UCARsgen Biotech LimitedOTHER
Brief Summary: This is a Phase I/II, single-arm, open-label, multicenter clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM). The study aims to evaluate the safety, tolerability, efficacy, cellular kinetics, and immunogenicity of CT0596.
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Sep 1, 2026Estimated
Primary Completion Date: Dec 31, 2030Estimated
Completion Date: Apr 30, 2031Estimated

Study Record Dates

First Submitted: Aug 2, 2026
First Submitted that Met QC Criteria: Aug 9, 2026
First Posted: Aug 12, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 9, 2026
Last Update Posted: Aug 12, 2026Actual
Last Verified: Jul 2026

NCT06718270Recruiting

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

NCT06730256Recruiting

A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia

NCT05066022Unknown status

A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT05893693Unknown status

Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT05822037Unknown status

CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT06705725Not yet recruiting

Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma